Drug Profile
AZD 2115
Alternative Names: AZD-2115Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca; Pulmagen Therapeutics
- Developer AstraZeneca
- Class Antiasthmatics; Bronchodilators; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic M3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 30 Dec 2017 AstraZeneca completes a phase I trial in Healthy volunteers in Sweden (Inhalation) (NCT03097380)
- 31 Mar 2015 Discontinued - Phase-I for Chronic obstructive pulmonary disease (In volunteers) in United Kingdom (Inhalation)
- 31 Mar 2015 Discontinued - Phase-II for Chronic obstructive pulmonary disease in USA, Poland and Sweden (Inhalation)